HOUGEN ELIZABETH L 4

What Happened
Elizabeth L. Hougen, EVP, Finance & Chief Financial Officer of Ionis Pharmaceuticals (IONS), exercised option/derivative awards on March 16, 2026 to acquire 174,999 shares across four option lots (60,299 @ $60.89; 61,041 @ $56.78; 33,118 @ $32.60; 20,541 @ $37.58) for a total exercise cost of about $8.99 million. On March 16–17, 2026 she sold a total of 225,220 shares in open-market transactions, generating approximately $16.31 million in proceeds (sales reported as 205,608 @ $72.38 weighted avg; 9,440 @ $72.77 weighted avg; 10,172 @ $73.21 weighted avg). The filing also shows matching derivative “disposed” entries at $0.00 for the exercised lots (see Key Details).

Key Details

• Transaction dates: Exercises and most sales on 2026-03-16; additional sale on 2026-03-17. Form 4 filed 2026-03-18 (timely).
• Option exercise detail (aggregate): 174,999 shares exercised; aggregate cash paid ≈ $8.99M. Lot-level prices: $60.89, $56.78, $32.60, $37.58.
• Open-market sales: 225,220 shares sold for total proceeds ≈ $16.31M. Reported sale prices are weighted averages; per-footnote ranges: $71.70–$72.70, $72.71–$72.88, and $73.11–$73.28.
• Derivative disposals: The Form 4 lists zero-dollar disposals corresponding to the exercised lots (likely shares surrendered to satisfy exercise cost and/or tax withholding).
• 10b5‑1 plan: Footnote confirms the sales were made pursuant to a Rule 10b5‑1 trading plan adopted 2025-12-09.
• Shares owned after transaction: Not supplied in the material you provided—see the filed Form 4 for total post-transaction holdings.

Context and plain-language note: Hougen exercised stock options (a derivative exercise — Form 4 code M) and then sold shares in the open market. The combination of exercise plus zero-dollar derivative disposals suggests some exercised shares were used to cover exercise costs or tax obligations, while the open-market trades under a pre-established 10b5‑1 plan realized cash proceeds. This is typically routine insider liquidity rather than an explicit endorsement or criticism of company prospects.